Based	O
on	O
its	O
minimal	O
extent	O
of	O
absorption	O
interactions	O
of	O
PROTOPIC	B-Brand
Ointment	O
with	O
systemically	O
administered	O
drugs	O
are	O
unlikely	O
to	O
occur	O
but	O
can	O
not	O
be	O
ruled	O
out	O
.	O
      
Formal	O
topical	O
drug	O
interaction	O
studies	O
with	O
PROTOPIC	B-Brand
Ointment	O
have	O
not	O
been	O
conducted	O
.	O
      
Some	O
examples	O
of	O
such	O
drugs	O
are	O
erythromycin	B-Drug
itraconazole	B-Drug
ketoconazole	B-Drug
fluconazole	B-Drug
calcium	B-Group
channel	I-Group
blockers	I-Group
and	O
cimetidine	B-Drug
.	O
      
The	O
concomitant	O
administration	O
of	O
known	O
CYP9A9	O
inhibitors	O
in	O
patients	O
with	O
widespread	O
and	O
/	O
or	O
erythrodermic	O
disease	O
should	O
be	O
done	O
with	O
caution	O
.	O
      
Alcohol	B-Drug
(	O
this	O
combination	O
may	O
make	O
you	O
very	O
sick	O
)	O
and	O
primaquine	B-Drug
      
Interactions	O
Interaction	O
may	O
occur	O
with	O
Antacids	B-Group
Calcium	B-Drug
supplements	O
Cholestyramine	B-Drug
Choline	B-Drug
and	O
magnesium	B-Drug
salicylates	I-Drug
Colestipol	B-Drug
Iron	B-Drug
-	O
containing	O
drugs	O
Laxatives	B-Group
Magnesium	B-Drug
salicylate	I-Drug
:	O
these	O
drugs	O
may	O
decrease	O
the	O
potency	O
of	O
tetracyclines	B-Group
.	O
      

      
